On Friday, BioXcel Therapeutics Inc (NASDAQ: BTAI) was 15.37% up from the session before settling in for the closing price of $4.75. A 52-week range for BTAI has been $1.17 – $13.36.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 6.20%. When this article was written, the company’s average yearly earnings per share was at 78.20%. With a float of $13.21 million, this company’s outstanding shares have now reached $14.56 million.
Let’s determine the extent of company efficiency that accounts for 37 employees. In terms of profitability, gross margin is -151.61%, operating margin of -6314.17%, and the pretax margin is -5869.82%.
BioXcel Therapeutics Inc (BTAI) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward BioXcel Therapeutics Inc stocks. The insider ownership of BioXcel Therapeutics Inc is 9.29%, while institutional ownership is 4.34%. The most recent insider transaction that took place on Dec 16 ’24, was worth 58. In this transaction an insider of this company sold 165 shares at a rate of $0.35, taking the stock ownership to the 19,957 shares. Before that another transaction happened on Dec 16 ’24, when Company’s CEO and President sold 3,117 for $0.36, making the entire transaction worth $1,131. This insider now owns 59,605 shares in total.
BioXcel Therapeutics Inc (BTAI) Earnings and Forecasts
Going through the last 3-months fiscal report unveiled on the 9/30/2024, it has been observed that the corporation posted -5.12 earnings per share (EPS) during the time that was better than consensus figure (set at -7.68) by 2.56. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.65 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 78.20% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 61.76% during the next five years compared to 6.20% growth over the previous five years of trading.
BioXcel Therapeutics Inc (NASDAQ: BTAI) Trading Performance Indicators
You can see what BioXcel Therapeutics Inc (BTAI) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 0.74. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 91.69.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -12.67, a number that is poised to hit -1.22 in the next quarter and is forecasted to reach -3.00 in one year’s time.
Technical Analysis of BioXcel Therapeutics Inc (BTAI)
Looking closely at BioXcel Therapeutics Inc (NASDAQ: BTAI), its last 5-days average volume was 22.18 million, which is a jump from its year-to-date volume of 4.89 million. As of the previous 9 days, the stock’s Stochastic %D was 55.80%.
During the past 100 days, BioXcel Therapeutics Inc’s (BTAI) raw stochastic average was set at 62.37%, which indicates a significant increase from 61.65% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.23 in the past 14 days, which was higher than the 0.32 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.35, while its 200-day Moving Average is $3.89. However, in the short run, BioXcel Therapeutics Inc’s stock first resistance to watch stands at $5.95. Second resistance stands at $6.41. The third major resistance level sits at $7.34. If the price goes on to break the first support level at $4.56, it is likely to go to the next support level at $3.63. Should the price break the second support level, the third support level stands at $3.17.
BioXcel Therapeutics Inc (NASDAQ: BTAI) Key Stats
There are 6,056K outstanding shares of the company, which has a market capitalization of 79.77 million. As of now, sales total 2,270 K while income totals -59,600 K. Its latest quarter income was 170 K while its last quarter net income were -7,250 K.
